Wanbury Limited reported a significant contraction in profitability for the quarter ended June 30, 2026, with net profit after tax (PAT) falling 76.0% year-on-year to ₹3.2 crore. The decline was primarily driven by an unprecedented surge in input costs, particularly solvents and crude oil-linked materials, exacerbated by logistics disruptions in West Asia that delayed API export dispatches. Despite these headwinds, revenue from operations grew 1.5% to ₹165 crore, reflecting resilient demand for its active pharmaceutical ingredients (APIs) and domestic formulations.

The company filed its unaudited financial results with the Bombay Stock Exchange and National Stock Exchange of India Ltd under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing highlights a divergence between top-line stability and bottom-line pressure, as gross margins contracted to 52.5% from 54.0% in the corresponding quarter last year. Management attributes this margin erosion to timing mismatches in passing on inflationary costs to customers, a factor expected to resolve in subsequent quarters.

Financial Performance

The table below summarises Wanbury's key financial metrics for the quarter, reflecting the sharp divergence between revenue resilience and profitability compression.

*Includes Other Income

Earnings per share (EPS) dropped to ₹0.93 from ₹4.12 in Q1 FY26. Other income remained modest at ₹0.4 crore, up slightly from ₹0.3 crore in the prior year period. The severe compression in PAT margins — down 631 basis points year-on-year — underscores the immediate impact of supply chain shocks on operational efficiency.

Strategic Developments

Beyond financial metrics, Wanbury executed key strategic initiatives during the quarter. The company completed a refinancing of its debt facilities with Axis Finance Limited and Poonawalla Fincorp, availing aggregate borrowings of ₹205 crore. This move replaced existing high-cost borrowings, reducing the borrowing cost from 12.5% per annum to sub-10% per annum effective July 1, 2026. Consequently, the pledge on promoter shareholding of 1,42,03,818 equity shares (40.65% of paid-up capital) has been released.

Regulatory approvals continued to strengthen the company's global footprint:

• Australia: The Tanuku API manufacturing site cleared inspections by the Therapeutic Goods Administration (TGA), enabling exports of three additional APIs.
• Korea: The Patalganga facility completed Ministry of Food and Drug Safety (MFDS) inspections with zero observations, receiving its GMP certificate during the quarter.
• US: Subsequent to the quarter-end, on July 30, 2026, the USFDA issued a "No DMF deficiency letter" for Metformin HCl API across multiple ANDAs. A Certificate of Suitability for Riveroxaben API was received on July 31, 2026.
• New Markets: DMFs were filed for Diphenhydramine HCl in Malaysia and Singapore, and Paroxetine HCl in Korea and Latin America.

What the Numbers Show

The data reveals a temporary structural disconnect between revenue generation and cost absorption. While revenue growth remained positive at 1.5%, the inability to pass through sudden input cost inflation within the same quarter led to a disproportionate drop in profitability. The successful refinancing signals a reduction in future fixed costs, with management expecting finance cost benefits to flow through from Q2 FY27 onwards. This suggests that the current margin contraction is likely transitory rather than indicative of long-term operational weakness.

Wanbury Limited confirmed on July 30, 2026, that it has received no Drug Master File (DMF) deficiency letters from the United States Food and Drug Administration (USFDA) for multiple Abbreviated New Drug Applications (ANDAs). This regulatory clearance specifically pertains to ANDAs utilizing Wanbury’s Metformin Hydrochloride (HCl) Active Pharmaceutical Ingredient (API) across various formulations. The absence of deficiencies reinforces the company’s compliance standing with the USFDA, a critical factor for maintaining market access for its generic drug supplies.

USFDA Regulatory Compliance

The company disclosed this update in accordance with Regulation 30 of the Securities and Exchange Board of India (SEBI) Listing Obligations and Disclosure Requirements (LODR). The confirmation of no DMF issues is significant for stakeholders, as DMFs contain confidential technical data regarding the manufacturing, processing, and quality control of drug substances. A clean regulatory record facilitates the approval and continued marketing of generic medicines in the United States, which remains a key revenue driver for Indian pharmaceutical exporters.

South Korea API Expansion

In parallel with its US regulatory updates, Wanbury is actively expanding its international footprint by exploring new business opportunities in South Korea. The company has filed a new DMF for an additional API to supply this emerging market. This strategic move aims to diversify its customer base and strengthen its position in the global API supply chain. Management emphasized its commitment to supplying high-quality APIs to support human well-being in these new markets.

What the Numbers Show

The dual focus on maintaining strict compliance in the mature US market while aggressively pursuing entry into South Korea highlights Wanbury’s balanced growth strategy. By securing regulatory clarity for its Metformin HCl API — a widely used medication for diabetes management — the company mitigates supply chain risks associated with regulatory holds. Simultaneously, the expansion into South Korea indicates a proactive approach to capturing demand in Asia-Pacific markets, reducing dependency on any single geographic region for its API revenues.